Brief Reports Role of the MMP9 Gene in Hemorrhagic Transformations After Tissue-Type Plasminogen Activator Treatment in Stroke Patients
نویسندگان
چکیده
Israel Fernández-Cadenas, PhD*; Alberto del Río-Espínola, PhD*; Caty Carrera, MSc*; Sophie Domingues-Montanari, PhD; Maite Mendióroz, MD, PhD; Pilar Delgado, MD, PhD; Anna Rosell, PhD; Marc Ribó, MD, PhD; Dolors Giralt, MSc; Manolo Quintana, MSc; Mar Castellanos, MD, PhD; Victor Obach, MD, PhD; Sergi Martínez, MD, PhD; Mari Mar Freijo, MD; Jordi Jiménez-Conde, MD, PhD; Jaume Roquer, MD, PhD; Joan Martí-Fábregas, MD, PhD; Carlos A. Molina, MD, PhD; José Álvarez-Sabín, MD, PhD; Joan Montaner, MD, PhD
منابع مشابه
Role of the MMP9 gene in hemorrhagic transformations after tissue-type plasminogen activator treatment in stroke patients.
BACKGROUND AND PURPOSE Despite the benefits of tissue-type plasminogen activator treatment, some stroke patients experience adverse hemorrhagic transformations (HT). Plasma protein levels of MMP9 have been associated with HT occurrence. We aimed to analyze the association of the MMP9 gene with HT occurrence. METHODS We analyzed the MMP9 gene in blood samples from 885 stroke patients treated w...
متن کاملSafety and feasibility of intravenous thrombolytic therapy in Iranian patients with acute ischemic stroke
Background: Thrombolytic therapy is the only approved treatment for acute cerebral ischemia. The hemorrhagic transformation is the greatest complication of this treatment, which may occur after recanalization of occluded artery. The aim of this study was to determine factors associated with clinical improvement and worsening in patients with acute ischemic stroke treated with intravenous th...
متن کاملA clinical study investigating the three months prognosis of patients with ischemic stroke treated with recombinant tissue plasminogen activator (rt-PA) and its effective factors
Objective: Currently, treating ischemic stroke by intravenous thrombolytic therapy has acceptable results in patients with stroke. This study aimed to evaluate the three months prognosis of patients treated with recombinant tissue plasminogen activator (rt-PA).Methods: This cross-sectional prospective study was conducted on 30 patients with cerebral ischemic stroke with the National Insti...
متن کاملThe Outcome of Treatment With Recombinant Tissue Plasminogen Activator in Acute Ischemic Stroke
Background: Thrombolytic therapy is the recommended treatment of acute ischemic stroke. It is crucial to evaluate the treatment results with recombinant Tissue Plasminogen Activator (r-TPA) in patients with acute stroke. Objectives: This study aimed to evaluate treatment outcomes with r-TPA in patients with acute stroke in a referral stroke center in Iran. Materials & Methods: In this retrosp...
متن کاملThrombolysis in Stroke Patients; Problems and Limitations
Thrombolysis for stroke is being used in some developing countries. This study was designed to evaluate the problems of thrombolysis therapy in Iran. During January-July 2008, all patients with ischemic stroke admitted to Ghaem Hospital, Mashhad, northeast Iran, were enrolled in a prospective observational study. Ghaem Hospital is a tertiary care hospital that includes infrastructure for thromb...
متن کامل